drugset / Trial / NCT00136539
Neoadjuvant Therapy With Herceptin and Taxol for Breast Cancer
Phase 2
Completed
41 enrolled
Harold J. Burstein, MD, PhD
Beth Israel Deaconess Medical Center · collabBrigham and Women's Hospital · collabBristol-Myers Squibb · collabDana-Farber Cancer Institute · collabGenentech, Inc. · collabHarvard Vanguard Medical Associates · collabMassachusetts General Hospital · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the effectiveness and safety of administering Herceptin in combination with Taxol (paclitaxel) in the treatment of women with HER2-positive, early stage breast cancer prior to surgery.
Timeline
- Start
- 1999-03
- Primary completion
- 2006-11
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | — | Intravenous |
| Subject | Trastuzumab | Monoclonal antibody | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |